索里奥表示,阿斯利康后期管线和变革性技术使其有望实现2030年目标,2027年读数潜力超过200亿美元。
我们有四款新药获批,并公布了12项积极的III期项目读数,合计峰值年收入潜力远超100亿美元。2027年一系列丰富的后续读数潜力超过200亿美元。凭借多个处于后期开发阶段的潜在重磅资产以及快速规模化的变革性技术,我们有望实现2030年目标,并在下一个十年保持增长。原文 (en)
We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars. With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.